Can Net Receivables from 2010 to 2026

CANF Stock  USD 4.11  0.32  7.22%   
Can Fite's Net Receivables is decreasing over the last several years with very volatile swings. Net Receivables is predicted to flatten to about 84.1 K. During the period from 2010 to 2026 Can Fite Biopharma Net Receivables regressed destribution of quarterly values had coefficient of variationof  230.35 and r-value of (0.03). View All Fundamentals
 
Net Receivables  
First Reported
2011-09-30
Previous Quarter
78 K
Current Value
77 K
Quarterly Volatility
1.5 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Can Fite financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Can Fite's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6 K, Interest Expense of 12 K or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 18.39, Dividend Yield of 0.0 or PTB Ratio of 2.95. Can financial statements analysis is a perfect complement when working with Can Fite Valuation or Volatility modules.
  
Build AI portfolio with Can Stock
Check out the analysis of Can Fite Correlation against competitors.

Latest Can Fite's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Can Fite Biopharma over the last few years. It is Can Fite's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Can Fite's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Very volatile
   Net Receivables   
       Timeline  

Can Net Receivables Regression Statistics

Arithmetic Mean523,675
Geometric Mean105,952
Coefficient Of Variation230.35
Mean Deviation758,878
Median76,999
Standard Deviation1,206,288
Sample Variance1.5T
Range4M
R-Value(0.03)
Mean Square Error1.6T
R-Squared0.0008
Significance0.92
Slope(6,582)
Total Sum of Squares23.3T

Can Net Receivables History

202684.1 K
202588.5 K
202477 K
202378 K
202247 K
202148 K
202018 K

About Can Fite Financial Statements

Can Fite stakeholders use historical fundamental indicators, such as Can Fite's Net Receivables, to determine how well the company is positioned to perform in the future. Although Can Fite investors may analyze each financial statement separately, they are all interrelated. For example, changes in Can Fite's assets and liabilities are reflected in the revenues and expenses on Can Fite's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Can Fite Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables88.5 K84.1 K

Currently Active Assets on Macroaxis

When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:
Check out the analysis of Can Fite Correlation against competitors.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Can Biotechnology industry sustain growth momentum? Does Can have expansion opportunities? Factors like these will boost the valuation of Can Fite. Projected growth potential of Can fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Can Fite demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Revenue Growth
(0.36)
Return On Assets
(0.82)
Return On Equity
(2.64)
Understanding Can Fite Biopharma requires distinguishing between market price and book value, where the latter reflects Can's accounting equity. The concept of intrinsic value—what Can Fite's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Can Fite's price substantially above or below its fundamental value.
It's important to distinguish between Can Fite's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Can Fite should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Can Fite's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.